https://orcid.org/0000-0003-4423-5496
Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Luca Filippi, Viviana Frantellizzi, Giuseppe De Vincentis & Orazio Schillaci. (2023) The new bone WB-SPECT/CT: hybrid, from head-to-toe and digital! Is it worth the effort?. Expert Review of Medical Devices 20:10, pages 791-795.
Read now
Read now
Luca Filippi, Luca Urso, Francesco Bianconi, Barbara Palumbo, Maria Cristina Marzola, Laura Evangelista & Orazio Schillaci. (2023) Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. Expert Review of Molecular Diagnostics 23:3, pages 243-255.
Read now
Read now
Luca Filippi, Barbara Palumbo, Viviana Frantellizzi, Susanna Nuvoli, Giuseppe De Vincentis, Angela Spanu & Orazio Schillaci. (2022) Prostate-specific membrane antigen-directed imaging and radioguided surgery with single-photon emission computed tomography: state of the art and future outlook. Expert Review of Medical Devices 19:11, pages 815-824.
Read now
Read now
Joana Gorica, Maria Silvia De Feo, Luca Filippi, Viviana Frantellizzi, Orazio Schillaci & Giuseppe De Vincentis. (2022) Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives. Expert Review of Molecular Diagnostics 22:11, pages 991-996.
Read now
Read now
Luca Filippi, Antonia Dimitrakopoulou-Strauss, Laura Evangelista & Orazio Schillaci. (2022) Long axial field-of-view PET/CT devices: are we ready for the technological revolution?. Expert Review of Medical Devices 19:10, pages 739-743.
Read now
Read now
Articles from other publishers (21)
Luca Filippi, Luca Urso, Orazio Schillaci & Laura Evangelista. (2023) [18F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review. Diagnostics 13:15, pages 2613.
Crossref
Crossref
Anne Laure Giraudet, Armelle Vinceneux, Valentin Pretet, Emilie Paquet, Alicia Sanchez Lajusticia, Fouzi Khayi, Jean Noël Badel, Helen Boyle, Aude Flechon & David Kryza. (2023) Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma. Pharmaceuticals 16:7, pages 995.
Crossref
Crossref
Michele Balma, Virginia Liberini, Ambra Buschiazzo, Manuela Racca, Alessio Rizzo, Daniele Giovanni Nicolotti, Riccardo Laudicella, Natale Quartuccio, Michelangelo Longo, Giorgia Perlo, Enzo Terreno, Ronan Abgral, Martin William Huellner, Alberto Papaleo & Désirée Deandreis. (2023) The Role of Theragnostics in Breast Cancer: A Systematic Review of the
Last 12 Years. Current Medical Imaging Formerly Current Medical Imaging Reviews 19:8.
Crossref
Crossref
Azik Hoffman & Gilad E. Amiel. (2023) The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective. Cancers 15:13, pages 3402.
Crossref
Crossref
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel O. Lawal, Kgomotso Mokoala, Janet Reed, Letjie Maseremule, Honest Ndlovu, Khanyi Hlongwa, Alex Maes, Alfred Morgenstern & Christophe Van de Wiele. (2023) 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. European Journal of Nuclear Medicine and Molecular Imaging 50:7, pages 2210-2218.
Crossref
Crossref
Ayaka Aso, Hinako Nabetani, Yoshifumi Matsuura, Yuichiro Kadonaga, Yoshifumi Shirakami, Tadashi Watabe, Taku Yoshiya, Masayoshi Mochizuki, Kazuhiro Ooe, Atsuko Kawakami, Naoya Jinno, Atsushi Toyoshima, Hiromitsu Haba, Yang Wang, Jens Cardinale, Frederik Lars Giesel, Atsushi Shimoyama, Kazuko Kaneda-Nakashima & Koichi Fukase. (2023) Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine. International Journal of Molecular Sciences 24:10, pages 8701.
Crossref
Crossref
Luca Filippi & Agostino Chiaravalloti. (2023) Prostate Cancer: From Molecular Imaging to Immunological and Target Therapies. Biomedicines 11:4, pages 1176.
Crossref
Crossref
Niranjan Meher, Henry F. VanBrocklin, David M. Wilson & Robert R. Flavell. (2023) PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer. Pharmaceuticals 16:2, pages 315.
Crossref
Crossref
Viviana Frantellizzi, Maria Ricci, Andrea Cimini, Luca Filippi, Miriam Conte, Maria Silvia De Feo & Giuseppe De Vincentis. (2023) The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How?. Applied Sciences 13:3, pages 1890.
Crossref
Crossref
Aadil Adnan & Sandip Basu. (2023) PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics 13:1, pages 158.
Crossref
Crossref
Motohide Uemura, Tadashi Watabe, Seiji Hoshi, Ryo Tanji, Kei Yaginuma & Yoshiyuki Kojima. (2023) The current status of prostate cancer treatment and PSMA theranostics. Therapeutic Advances in Medical Oncology 15.
Crossref
Crossref
Mei Li, Roman Zelchan & Anna Orlova. (2022) The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer. Biomedicines 10:10, pages 2533.
Crossref
Crossref
Santiago Brühlmann, Martin Kreller, Hans-Jürgen Pietzsch, Klaus Kopka, Constantin Mamat, Martin Walther & Falco Reissig. (2022) Efficient Production of the PET Radionuclide 133La for Theranostic Purposes in Targeted Alpha Therapy Using the 134Ba(p,2n)133La Reaction. Pharmaceuticals 15:10, pages 1167.
Crossref
Crossref
Eline A. M. Ruigrok, Giulia Tamborino, Erik de Blois, Stefan J. Roobol, Nicole Verkaik, Marijke De Saint-Hubert, Mark W. Konijnenberg, Wytske M. van Weerden, Marion de Jong & Julie Nonnekens. (2022) In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. European Journal of Nuclear Medicine and Molecular Imaging 49:11, pages 3627-3638.
Crossref
Crossref
Luca Filippi, Laura Evangelista, Mike M. Sathekge & Orazio Schillaci. (2022) ImmunoPET for prostate cancer in the PSMA era: do we need other targets?. Clinical and Translational Imaging 10:6, pages 587-596.
Crossref
Crossref
Luca FILIPPI & Arthur J. BRAAT. (2022) Theragnostics in primary and secondary liver tumors: the need for a personalized approach. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 65:4.
Crossref
Crossref
Mike M. Sathekge, Frank Bruchertseifer, Mariza Vorster, Alfred Morgenstern & Ismaheel O. Lawal. (2021) Global experience with PSMA-based alpha therapy in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 49:1, pages 30-46.
Crossref
Crossref
A. Paden King, Frank I. Lin & Freddy E. Escorcia. (2021) Why bother with alpha particles?. European Journal of Nuclear Medicine and Molecular Imaging 49:1, pages 7-17.
Crossref
Crossref
Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka, Alexander R. Haug, Marcus Hacker, Markus Hartenbach & Sazan Rasul. (2021) Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Current Oncology 28:5, pages 3692-3704.
Crossref
Crossref
Kgomotso Mokoala, Ismaheel Lawal, Thabo Lengana, Mankgopo Kgatle, Frederik L. Giesel, Mariza Vorster & Mike Sathekge. (2021) PSMA Theranostics: Science and Practice. Cancers 13:15, pages 3904.
Crossref
Crossref
Luca Filippi, Viviana Frantellizzi, Agostino Chiaravalloti, Mariano Pontico, Maria Silvia De Feo, Ferdinando Corica, Melissa Montebello, Orazio Schillaci, Giuseppe De Vincentis & Oreste Bagni. (2021) Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences 22:6, pages 3036.
Crossref
Crossref